Clinical trials · Pennsylvania
Idiopathic Pulmonary Fibrosis clinical trials in Pennsylvania
We’re tracking 14 recruiting idiopathic pulmonary fibrosis studies with a site in Pennsylvania — including Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT07671911RecruitingPhase 3
Cough relief for pulmonary fibrosis
This trial tests a new extended-release medicine, nalbuphine, to reduce chronic coughing in people with idiopathic pulmonary fibrosis (a lung disease that scars the lungs). It may help make cough less frequent and less bothersome.
DuBois, PennsylvaniaAges 40 years+ - NCT07284602RecruitingPhase 3
Comparing a new drug to pirfenidone for lung scarring
This trial tests a new medicine, LYT-100 (deupirfenidone), against the standard drug pirfenidone for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the new drug works better or has fewer side effects.
DuBois, PennsylvaniaAges 40 years+ - NCT07230288RecruitingPhase 2
Study of ABBV-142 for Idiopathic Pulmonary Fibrosis
This trial is testing a new antibody drug, ABBV-142, to see if it can reduce disease activity in adults with idiopathic pulmonary fibrosis (IPF). It may help if your IPF was diagnosed within the last 7 years and you meet certain health criteria.
Philadelphia, PennsylvaniaAges 40 years+ - NCT06951217RecruitingPhase 2
Long-term safety study of an inhaled drug for lung scarring
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05975983RecruitingPhase 2
Oral treatment test for idiopathic pulmonary fibrosis
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
Philadelphia, PennsylvaniaAges 40 years+ - NCT05571059RecruitingPhase 2
Oral ifetroban for idiopathic pulmonary fibrosis
This trial tests an oral medication, ifetroban, to see if it can slow the progression of idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to improve breathing and lung function in patients with IPF.
Philadelphia, PennsylvaniaAges 40 years+ - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Hershey, PennsylvaniaAges 40 years+ - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Philadelphia, PennsylvaniaAges 21 years+ - NCT00258570Recruiting
Study genetics in idiopathic pulmonary fibrosis patients
This study looks at genetic differences in people with idiopathic pulmonary fibrosis (a lung scarring condition with no known cause). It may help researchers understand what influences the disease and guide future treatment options.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT00373841Recruiting
Study of genetic and protein changes in idiopathic pulmonary fibrosis
This study looks at genetic (DNA) and protein changes over time in people with idiopathic pulmonary fibrosis, to better understand how the disease progresses. Your participation may help researchers learn patterns that could guide future care.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07201922RecruitingPhase 3
Can a new pill help slow lung changes in people with family risk?
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
Philadelphia, PennsylvaniaAges 40 years+ - NCT07869147RecruitingPhase 2
Study of ORJ-001 for idiopathic pulmonary fibrosis
This trial tests a new medicine, ORJ-001, for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help slow the disease and improve breathing.
DuBois, PennsylvaniaAges 40 years+ - NCT07652658RecruitingPhase 2
Study of AZD8965 for people with IPF
This trial tests a new drug called AZD8965 for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the drug can help people with IPF either on current treatments or not on standard therapy.
Bethlehem, PennsylvaniaAges 40 years+ - NCT03500731RecruitingPhase 1/Phase 2
Lung and bone marrow transplant for lung and blood failure
This Phase 1/2 study tests a special lung-and-bone-marrow transplant approach for people with severe lung disease and bone marrow failure (low blood counts). The goal is to see if the treatment is safe and whether it can improve outcomes when standard long-term immune-suppressing medicines are a poor fit.
Pittsburgh, PennsylvaniaAges 18–60
Idiopathic Pulmonary Fibrosis trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting idiopathic pulmonary fibrosis studies listed above.
- Temple University Hospital · 4 studies
- Thomas Jefferson University · 3 studies
- Clinical Research Associates of Central Pennsylvania · 2 studies
- Clinical Research Associates of Central PA
- Hospital of the University of Pennsylvania
- Jefferson Health Honickman Center /ID# 279127
- Michelle F MacPherson
- Penn State Milton S Hershey Medical Center
What taking part in a idiopathic pulmonary fibrosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Idiopathic Pulmonary Fibrosis trials in other states
Common questions
- Are there idiopathic pulmonary fibrosis clinical trials in Pennsylvania?
- Yes. We're currently tracking 14 recruiting idiopathic pulmonary fibrosis studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a idiopathic pulmonary fibrosis study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a idiopathic pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New idiopathic pulmonary fibrosis studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.